{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:34:26Z","timestamp":1793021666628,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanmic.2026.101467","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:00Z","timestamp":1784748600000},"page":"101467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-8417","authenticated-orcid":false,"given":"Benjamin","family":"Davido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Saleh-Mghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9035-4417","authenticated-orcid":false,"given":"Pierre","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rottman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101467_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101467_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs : no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lanmic.2026.101467_bib7","article-title":"Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach","volume":"61","author":"Davido","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanmic.2026.101467_bib8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S1473-3099(20)30995-6","article-title":"Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial","volume":"21","author":"Fran\u00e7ois","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-022-04204-9","article-title":"Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial","volume":"26","author":"Chastre","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.lanmic.2026.101467_bib10","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2025.10144","article-title":"Navigating recurrent Clostridioides difficile infection without Bezlotoxumab: potential challenges ahead","volume":"5","author":"Arya","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.lanmic.2026.101467_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2025.1652946","article-title":"Efficacy, immunogenicity, and safety of pneumococcal conjugate vaccine in children: a systematic review and meta-analysis","volume":"13","author":"Dai","year":"2025","journal-title":"Front Pediatr"},{"key":"10.1016\/j.lanmic.2026.101467_bib12","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2666-5247(22)00303-2","article-title":"The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline","volume":"4","author":"Frost","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101467_bib13","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41564-025-02070-z","article-title":"Challenges and opportunities in mRNA vaccine development against bacteria","volume":"10","author":"Aernout","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.lanmic.2026.101467_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molmed.2024.02.013","article-title":"mRNA vaccine platforms to prevent bacterial infections","volume":"30","author":"Bergstrom","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.lanmic.2026.101467_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108492","article-title":"Current innovations in mRNA vaccines for targeting multidrug-resistant ESKAPE pathogens","volume":"79","author":"Imani","year":"2025","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.lanmic.2026.101467_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313139","article-title":"Current progress in the development of mRNA vaccines against bacterial infections","volume":"25","author":"Khlebnikova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lanmic.2026.101467_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41541-025-01202-0","article-title":"Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease","volume":"10","author":"Higham","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10096-023-04548-2","article-title":"Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers","volume":"42","author":"Campos-Madueno","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"suppl 4","key":"10.1016\/j.lanmic.2026.101467_bib19","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1093\/infdis\/jiaa537","article-title":"Hib vaccines: their impact on Haemophilus influenzae type b disease","volume":"224","author":"Gilsdorf","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/microorganisms9050886","article-title":"Long term impact of conjugate vaccines on Haemophilus influenzae meningitis: narrative review","volume":"9","author":"Slack","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.lanmic.2026.101467_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.13.2.302","article-title":"Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates","volume":"13","author":"Peltola","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.lanmic.2026.101467_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3201\/eid2801.210734","article-title":"Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe","volume":"28","author":"Hanquet","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib24","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2468-2667(24)00189-0","article-title":"New-generation pneumococcal vaccines for children","volume":"9","author":"De Wals","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.lanmic.2026.101467_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13756-023-01272-6","article-title":"The impact of influenza and pneumococcal vaccination on antibiotic use: an updated systematic review and meta-analysis","volume":"12","author":"van Heuvel","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.lanmic.2026.101467_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cmi.2019.06.030","article-title":"Impact of vaccination on antibiotic usage: a systematic review and meta-analysis","volume":"25","author":"Buckley","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101467_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00428-16","article-title":"How can vaccines contribute to solving the antimicrobial resistance problem?","volume":"7","author":"Lipsitch","year":"2016","journal-title":"mBio"},{"issue":"suppl 7","key":"10.1016\/j.lanmic.2026.101467_bib28","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1093\/cid\/ciad562","article-title":"Vaccination to reduce antimicrobial resistance burden-data gaps and future research","volume":"77","author":"Tadesse","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101040","article-title":"Impact of vaccines in reducing antimicrobial resistance","volume":"6","author":"Jesudason","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101467_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/1469-0691.12570","article-title":"Where does a Staphylococcus aureus vaccine stand?","volume":"20","author":"Fowler","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101467_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2023.2179486","article-title":"Towards an effective Staphylococcus vaccine: why have candidates failed and what is the next step?","volume":"22","author":"Tsai","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw246","article-title":"Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis","volume":"4","author":"Alevizakos","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41541-025-01244-4","article-title":"A multivalent mRNA-LNP cocktail vaccine confers superior efficacy against Staphylococcus aureus infection in murine models","volume":"10","author":"Gao","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib34","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/infdis\/jiaf600","article-title":"Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: a first-in-human phase I\/II randomized and controlled study","volume":"233","author":"Alaimo","year":"2026","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib36","author":"Sanofi"},{"key":"10.1016\/j.lanmic.2026.101467_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1668937","article-title":"An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodents","volume":"16","author":"Roier","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2026.101467_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141164","article-title":"IsdB antibody-mediated sepsis following S aureus surgical site infection","volume":"5","author":"Nishitani","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.lanmic.2026.101467_bib39","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1073\/pnas.1717161115","article-title":"Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR","volume":"115","author":"Sevilla","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lanmic.2026.101467_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100096","article-title":"Realising the broader value of vaccines in the UK","volume":"8","author":"Brassel","year":"2021","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanmic.2026.101467_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2215149","article-title":"Economic and cost-effectiveness aspects of vaccines in combating antibiotic resistance","volume":"19","author":"Yemeke","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2026.101467_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/cid\/ciad218","article-title":"Efficacy of a 4-antigen Staphylococcus aureus vaccine in spinal surgery: the STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) randomized clinical trial","volume":"77","author":"Hassanzadeh","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/femsre\/fuz030","article-title":"Development of a vaccine against Staphylococcus aureus invasive infections: evidence based on human immunity, genetics and bacterial evasion mechanisms","volume":"44","author":"Miller","year":"2020","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.lanmic.2026.101467_bib44","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2013.3010","article-title":"Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial","volume":"309","author":"Fowler","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.lanmic.2026.101467_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","article-title":"Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza","volume":"6","author":"Chivukula","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.lanmic.2026.101467_bib47","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.vaccine.2019.04.039","article-title":"The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101467_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.lanmic.2026.101467_bib49","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s40121-022-00648-2","article-title":"Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: a narrative review","volume":"11","author":"Napuri","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.lanmic.2026.101467_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lanmic.2026.101467_bib51","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2026.101467_bib52","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44259-025-00100-8","article-title":"Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae","volume":"3","author":"Cabrera","year":"2025","journal-title":"npj Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2026.101467_bib54","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101467_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101063","article-title":"How can the gut microbiome be targeted to fight multidrug-resistant organisms?","volume":"6","author":"Davido","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101467_bib56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3201\/eid3006.231338","article-title":"Decolonization and pathogen reduction approaches to prevent antimicrobial resistance and healthcare-associated infections","volume":"30","author":"Mangalea","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib57","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijantimicag.2016.08.021","article-title":"Colonisation with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis","volume":"48","author":"Alevizakos","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.lanmic.2026.101467_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajic.2015.12.005","article-title":"Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review","volume":"44","author":"Tischendorf","year":"2016","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.lanmic.2026.101467_bib59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.tim.2022.01.013","article-title":"Gut microbiome signatures and host colonization with multidrug-resistant bacteria","volume":"30","author":"Isles","year":"2022","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.lanmic.2026.101467_bib60","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/antibiotics14090890","article-title":"Gut microbiome and intestinal colonization with multidrug-resistant strains of Enterobacterales: an interplay between microbial communities","volume":"14","author":"Kocsis","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.lanmic.2026.101467_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2563709","article-title":"Gut microbiota as a regulator of vaccine efficacy: implications for personalized vaccination","volume":"17","author":"Lu","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.lanmic.2026.101467_bib62","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41541-024-01000-0","article-title":"Systematic review of the impact of intestinal microbiota on vaccine responses","volume":"9","author":"Ardura-Garcia","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.lanmic.2026.101467_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/cid\/cix411","article-title":"Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms","volume":"65","author":"Barrasa-Villar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101467_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01426-24","article-title":"Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR)","volume":"69","author":"Cornistein","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101467_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202200130","article-title":"Outer membrane vesicle-coated nanoparticle vaccine protects against Acinetobacter baumannii pneumonia and sepsis","volume":"3","author":"Bjanes","year":"2023","journal-title":"Adv Nanobiomed Res"},{"key":"10.1016\/j.lanmic.2026.101467_bib66","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1038\/s41467-025-61559-7","article-title":"Poly-\u03b2-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities","volume":"16","author":"Liao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2026.101467_bib67","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/dkv448","article-title":"Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Skurnik","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:48:20Z","timestamp":1793018900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S2666524726001229"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101467","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines for multidrug-resistant bacteria: promise, challenges, and microbiome-informed strategies","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101467"}}